Preparation Of Radionuclides And Their Measurement By High Resolution γ-Spectrometry, β-Spectrometry And High Resolution α-Spectrometry
The use of High Specific Activity Radionuclides HSARNs, obtained by either proton, deuteron or alpha cyclotron irradiation, followed by selective radiochemical separation from the irradiated target in No Carrier Added (NCA) form, is a powerful analytical tool. The main applications of these radionuclides are to medical dignosis and therapy in addition to toxicological, environmental and industrial studies. These NCA radionuclides and their Specific Activity (AS) can reach values close to the theoretical “carrier-free ” one AS(CF). The “real ” AS(NCA) must by measured by either analytical or/and radioanalytical techniques. The “accurate ” knowledge of behavior of cross-sections of each reaction, as a function of beam energy (excitation functions) is mandatory. The minimization of Isotopic Dilution Factor is achieved also. Some examples of production and radioanalytical quality control methods for HSARNs are presented.
Keywordsγ-spectrometry α-spectrometry β-spectrometry radionuclide measurements HSARNs
Unable to display preview. Download preview PDF.
- 3.Bonardi M et al. (1988) Fundamental parameters for the optimization of yield and radionuclidic purity of accelerator produced radioisotopes. Part I: thin-target excitation functions. Phys Med 1:23–46Google Scholar
- 4.Bonardi M et al. (1988) Fundamental parameters for the optimization of yield and radionulidic purity of accelerator produced radioisotopes. Part II: beam control and monitoring. Phys Med 2:83–101Google Scholar
- 6.Birattari C et al. (2001) Review of cyclotron production and quality control of high specific activity radionuclides for biomedical, biological, industrial and environmental applications at INFN-LASA. Proceeding International Congress on Cyclotrons and Their Applications, Cyclotron2001, East Lansing, MI, May 2001. American Institute of Physics, Melville, NYGoogle Scholar
- 8.Bonardi M (1988) The contribution to nuclear data for medical radioisotope production from the Milan Cyclotron Laboratory, IAEA Consultant's Meeting on “Nuclear Data Requirements for Medical Radioisotope Production ”, Tokyo, April 1987, IAEA Document, INDC(NDS)-195/GZ, IAEA, Vienna, Jan. 1988, pp. 98–112Google Scholar
- 9.IAEA-TECDOC-1211 Charged-particle cross-section database for medical radioisotope production. Co-ordinated Research Project (1995–1999). IAEA Vienna, Austria, May 2001 Available online at: http://www-nds.iaea.org/medical/
- 11.Groppi F et al. (2005) The use of liquid scintillation counting as a very sensitive radioanalytical tool for the determination of alpha, beta and electron emitting impurities in radiopharmaceutical compounds. J Radioanal Nucl Chem 263:521–525Google Scholar
- 18.Ridone S et al. (2004) Radioanalytical quality control on beta-emitting [186gRe]- and [153Sm]-radiopharmaceutical compounds for bone metastases pain palliation. World J Nucl Med 3:241Google Scholar
- 19.Persico E et al. (2006) Proton and deuteron cyclotron production studies of high specific activity 186gRe for radiotherapy. Technetium, Rhenium and other metals in Chemistry and Nuclear Medicine, SGE Editoriali, Padova, Italia, 7:613–614Google Scholar
- 20.Groppi F et al. (2005) Accurate determination of radionuclidic purity and half-life of reactor produced Lu-177g for metabolic radioimmunotherapy, World SciCo Singapore, 710–714Google Scholar